摘要
目的探讨低分子肝素联合双嘧达莫对骨科下肢深静脉血栓形成(DVT)患者D-二聚体(D-D)及血流指标的影响。方法选取2013年1月至2014年12月收治的下肢骨折患者术后并发DVT的84例患者为研究对象,随机分为观察组与对照组,每组42例。对照组于术后24 h内给予双嘧达莫口服,观察组在对照组治疗的基础上于脐旁2 cm处皮下注射低分子肝素钙。观察比较两组的治疗效果及并发症发生情况。结果观察组总有效率为95.24%,对照组为76.19%,差异有统计学意义(P<0.05)。结论低分子肝素联合双密哒莫能有效改善DVT患者D-D水平及抗血小板聚集,可提高DVT治疗效果,安全可靠,值得临床推广应用。
Objective To investigate the effect of D-dimer and blood indicators of low molecular weight heparin and dipyri- damole on patients with deep vein thrombosis （DVT）. Methods Selected 84 cases of patients with lower limb fracture and post- operative DVT from January 2013 to December 2014 as research subjects, and divided them into observation group（n = 42） and control group （ n = 42）. Patients in control group oral dipyridamole within 24 h after operation, patients in observation group sub- cutaneous low-molecular-weight heparin calcium navel on the basis of comtrol group. The therapeutic effect and complication of the two groups were observed and compared. Results The total effective rate of observation group and control group were 95.24% and 76. 19%, and the difference was significant （P 〈 0. 05 ）. Conclusion The low molecular weight heparin and double-density da monensin safely improve D-D levels in patients with DVT and anti-platelet aggregation, so it is worthy of being promotion.
出处
《临床医学》
CAS
2016年第6期13-14,共2页
Clinical Medicine
关键词
低分子肝素
双密达莫
深静脉血栓形成
Low molecular weight heparin
Dipyridamole
Deep vein thrombosis
